Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03452488
Other study ID # BIO101-CL03
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 24, 2018
Est. completion date January 20, 2021

Study information

Verified date July 2021
Source Biophytis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SARA-INT is a phase 2 interventional study performed in Europe and USA aimed to evaluate the clinical benefits, safety and tolerability of the investigational drug BIO101 administered orally for a six-month (26 weeks) duration to older patients, community dwelling men and women aged ≥65 years, suffering from age-related sarcopenia (including sarcopenic obesity), and at risk of mobility disability. The double-blind, placebo controlled clinical trial will collect and analyse data on physical performance and body composition and will specifically focus on the change of one functional measurement, the gait speed measured during the 400MW test plus the change of a highly standardised patient reported outcome (PRO), the physical function domain PF-10 at the SF-36 auto-evaluation questionnaire, in order to estimate the efficacy of BIO101 administered over 26 weeks, in preventing mobility disability in the target population.


Description:

SARA-INT is a three- arm interventional, phase 2, randomized, double blind placebo controlled clinical trial. It will be conducted in the EU (Belgium, France and Italy) and in the US. 334 community dwelling older adults (men or women≥65 years) reporting loss of physical function and considered at risk of mobility disability, will be selected to perform SPPB (Short Physical Performance Battery)1 tests. Those with SPPB scores ≤ 8 will be selected to perform body composition analysis with DEXA Scan. (DEXA Scans performed no more than 8 weeks before the date of randomization will be acceptable and in that case should not be repeated up to the end of the study visit). Participants with ALM/BMI < 0.789 in men and < 0.512 in women, or ALM <19.75kg in men and <15.02kg in women corresponding to the operational definition of sarcopenia according to the criteria of FNIH, will be definitively included and randomized if other inclusion/exclusion criteria are also satisfied. The overarching objective of SARA-INT clinical trial is to evaluate the efficacy and safety of BIO101 26-week oral administration on the prevention of mobility disability in at-risk, community dwelling older adults (≥65 years) reporting loss of physical function over the previous year, and in particular: 1. To estimate treatment effect improvement on physical function after six-month treatment versus placebo in the target population. 2. To estimate treatment effect on decrease of risk of mobility disability after six-month treatment versus placebo in the target population. The primary objective of SARA-INT is to evaluate the effects of two daily doses of BIO101 versus placebo on mobility function as measured by the gait speed during the 400MW test The first key secondary objective is to evaluate the effect of BIO101 on physical function from the patient's perspective using an adapted patient reported outcome (PRO). The second key objective is to assess on a simplified function test, i.e. raising from a chair, a minimal clinically significant benefit on mobility. SARA-INT other secondary objectives are: To assess changes in body composition and specifically on appendicular lean body mass, which is an expression of sarcopenia; To estimate the change of 400MW test as a dichotomous variable, for possible use in further studies; To estimate the effect on muscular strength; To assess the overall change on SPPB as cumulative expression of a physically frail status; To estimate the effect on a sarcopenia specific PRO, in view of future studies. SARA-INT exploratory objectives are: 1. To compare plasma and/or urinary levels of putative biomarkers of sarcopenia and of drug activity, and calculate their correlation with physical function changes over the study duration. 2. To compare change from baseline of the estimated cumulative daily activity as continuously recorded via a connected wearable actimeter device. A selection of physical activity indexes (by actimetry) will be described and a correlation with primary and key secondary outcome will be tested. The study plan is divided in a) screening and randomization phase; and b) treatment and evaluation phase and c) post-treatment follow-up. The recruitment is estimated to last 24 months. The investigational phase will comprise three main visits, the inclusion visit, the 3-month evaluation and the 6-month final evaluation visit, plus an intermediate visit after 1-month focused on safety assessment. Telephone interviews will be conducted at 5 months and 6 weeks after the end of treatment.


Recruitment information / eligibility

Status Completed
Enrollment 233
Est. completion date January 20, 2021
Est. primary completion date December 30, 2020
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged = 65 years and living in the community, reporting loss of physical function over the last 6-12 months 4. Short Physical Performance Battery (SPPB) score = 8 5. ALM/BMI < 0.789 in men and 0.512 in women, or ALM < 19.75kg in men and <15.02kg in women, as measured by DEXA scan 6. Ability to take oral medication and be willing to adhere to the study intervention regimen. 7. Agreement to adhere to Lifestyle Considerations throughout study duration 8. In the US, women and members of minority groups must be included in accordance with the NIH Policy on Inclusion of Women and Minorities as Participants In Research Involving Human Subjects. Exclusion Criteria: 1. Current use of anabolic drugs e.g. testosterone; current use of Erythropoietin; current use of corticosteroid agents (except local administration route, like eye drops or dermatologic formulations) 2. Non-menopausal women (however ongoing replacement hormonal treatment is not an exclusion criterion) 3. Known allergic reactions to components of the investigational drug (i.e. stemmacantha carthamoides leaves and roots). 4. Febrile illness within 7 days 5. Treatment with another investigational drug or other intervention within three months 6. Unable to understand and perform the functional tests, as judged by the Investigator 7. Inability to perform the 400MW test within 15 minutes 8. Clinical conditions: 1. Current diagnosis of major psychiatric disorders. 2. Alcohol abuse or dependence 3. Severe arthritis 4. Cancer requiring active treatment (cancer treated with chemotherapy, or radiotherapy and currently on remission is not an exclusion criterion) 5. Lung disease requiring regular use of supplemental oxygen 6. Inflammatory conditions requiring regular use of oral or parenteral corticosteroid agents 7. Severe cardiovascular disease (including New York Heart Association [NYHA] class III or IV congestive heart failure, clinically significant valvular disease, history of cardiac arrest, presence of an implantable defibrillator, or uncontrolled angina) 8. Parkinson's disease or other progressive neurological disorder 9. Renal disease requiring dialysis, or known renal insufficiency (moderate or severe reduction in GFR=30 ml/min/1.73 m2) 10. Chest pain, severe shortness of breath, or occurrence of other safety concerns during the baseline functional tests 400-meter walk test or 6MWT 11. History or active signs or symptoms of gallbladder/biliary disease (e.g. previous episodes of cholestasis/biliary tract obstruction, cholelithiasis, cholecystitis, etc.). Of note, history of cholecystectomy and no active biliary signs or symptoms, is not an exclusion criterion. 9. Current physical/rehabilitation therapy (except for passive physical therapy. However, this should not be initiated the week before an evaluation visit and once started, it should be maintained over the study duration).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BIO101
Oral capsules containing the BIO101 active principle is 20-hydroxyecdysone (20E) at 97%. Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate.
Placebo oral capsule
Oral capsules containing Microcrystalline cellulose, Colloidal anhydrous silica

Locations

Country Name City State
Belgium Vrije Universiteit Brussel Bruxelles
Belgium Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Centrum voor metabole botziekten Leuven
Belgium Université de Liège Liège
United States New Mexico Clinical Research & Osteoporosis Center Albuquerque New Mexico
United States Tekton Research Austin Texas
United States Advanced Clinical Research Banning California
United States Pennington Biomedical Research Center Baton Rouge Louisiana
United States Jean Mayer USDA Human Nutrition research Center on Aging Tufts University Boston Massachusetts
United States Institut On Aging Gainesville Florida
United States SC Clinical Research, Inc Garden Grove California
United States Medical Center Houston Texas
United States Jax-Ascent University of Florida Jacksonville Florida
United States PANAX Clinical Research Miami Lakes Florida
United States Columbia University New York New York
United States Clinical Research of Central Florida Plant City Florida
United States Science Advancing Medicine Clinical Research Center San Antonio Texas
United States The University of Texas Health Science Center at San Antonio San Antonio Texas
United States California Research Foundation San Diego California
United States Advanced Clinical Research West Jordan Utah
United States PMJ Research of Wilmington Wilmington North Carolina
United States Bowman Gray Center for Medical Education-of- Wake Forest School of Medicine Winston-Salem North Carolina
United States Tekton Research Yukon Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Biophytis

Countries where clinical trial is conducted

United States,  Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Biomarkers Biomarkers specific to Sarcopenia, to the Renin Angiotensin System Change from Baseline Biomarkers to measurement at 6 months
Other Actimetry The continuous physical activity of the volunteers will be recorded using a specific device during the 6-month study period. Change from actimetry at Month 0 to measurement at 6 months
Primary Gait speed measured during the 400MW test. The 400MWT is a measure of how long it takes a participant to walk a distance of 400 m. it is express in m/s The change from baseline to month 6 will be compared between groups of treatment (each dose versus placebo).
Secondary PF-10 subscore of the SF-36 Electronically self administrated or filling a paper booklet Patient Reported Outcome SF-36 will be assessed through a SF-36 questionnaire.
The physical function score (PF-10), role limitations due to physical problems.
The change from baseline to month 6 will be compared between groups of treatment (each dose versus placebo)
Secondary Appendicular Lean Body Mass Body composition especially Lean Body Mass in kg measured using DEXA. This will allow definition of the appendicular Lean Body mass The change from baseline to month 6 will be compared between groups of treatment (each dose versus placebo)
Secondary Body Fat Mass Body composition especially Fat Mass will be measured in kg. This will allow definition of the body Fat mass The change from baseline to month 6 will be compared between groups of treatment (each dose versus placebo)
Secondary 400MW test rate of success to complete the test The 400MW rate of success is the ability to complete the test at all (yes/no). The change from baseline to month 6 will be compared between groups of treatment (each dose versus placebo)
Secondary handgrip test The grip strength will be measured using the appropriate dynamometer. Strength in kg will be measured 3 times for both hands and the highest value will be kept for further analysis. Change from Baseline Grip Strength to measurement at 6 months
Secondary Knee extension test The knee extension in kg measurement will be performed using isokinetic dynamometer. Change from Baseline Knee extension to measurement at 6 months
Secondary Stair Climb Power Test The ability to ascend and descend stairs (9 stairs of 20 cm height) will be assessed in a specific period of time Change from Baseline Stair Climb Power Test to measurement at 6 months
Secondary SPPB Physical performance tests corresponding to standing balance, walking speed and chair stand will be assessed Change from Baseline SPPB to measurement at 6 months
Secondary Patient Reported Outcomes : SarQoL: Sarcopenia Quality of Life Electronically self administrated or filling a paper booklet Patient Reported Outcome SarQoL will be assessed through the SarQoL. The SarQoL® is composed of 22 questions including in total 55 items rated on a 4-point Likert scale. The questionnaire is scored, through a scoring algorithm, on 100 points, with higher scores reflecting a better quality of life. The change from baseline to month 6 will be compared between groups of treatment (each dose versus placebo)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Recruiting NCT05063279 - RELIEF - Resistance Training for Life N/A
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Recruiting NCT06143592 - Inspiratory Muscle Training on Balance, Falls and Diaphragm Thickness in the Elderly N/A
Terminated NCT04350762 - Nutritional Supplementation in the Elderly With Weight Loss N/A
Enrolling by invitation NCT05953116 - Managing the Nutritional Needs of Older Filipino With Due Attention to Protein Nutrition and Functional Health Study N/A
Recruiting NCT04028206 - Resistance Exercise or Vibration With HMB for Sarcopenia N/A
Enrolling by invitation NCT03297632 - Improving Muscle Strength, Mass and Physical Function in Older Adults N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A
Completed NCT03234920 - Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation N/A
Recruiting NCT03998202 - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Recruiting NCT04717869 - Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty
Completed NCT05497687 - Strength-building Lifestyle-integrated Intervention N/A
Completed NCT03119610 - The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity Phase 1/Phase 2
Recruiting NCT05711095 - The Anabolic Properties of Fortified Plant-based Protein in Older People N/A
Recruiting NCT05008770 - Trial in Elderly With Musculoskeletal Problems Due to Underlying Sarcopenia - Faeces to Unravel Gut and Inflammation Translationally
Not yet recruiting NCT05860556 - Sustainable Eating Pattern to Limit Malnutrition in Older Adults
Recruiting NCT04545268 - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance N/A
Recruiting NCT04522609 - Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant N/A
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease